New Screening non- invasive tool for Nonalcoholic Steatohepatitis in High-Risk Individuals | ||
| Zagazig University Medical Journal | ||
| Article 576, Volume 27, Issue 3, May 2021, Pages 538-550 PDF (647.98 K) | ||
| Document Type: Original Article | ||
| DOI: 10.21608/zumj.2020.33313.1883 | ||
| Authors | ||
| Yahya Mohamed Elhamdi* 1; Alaa Ahmed Farag2; Ayman Magd Eldin Mohammed Sadek3; Sameh Saber Bayoumi4 | ||
| 1M.B.B.Ch, Faculty of Medicine – Zagazig University | ||
| 2Assistant Professor of Internal Medicine, Faculty of Medicine, Zagazig University | ||
| 3Lecturer of Internal Medicine, Faculty of Medicine, Zagazig University | ||
| 4Assistant Professor of Radiology, Faculty of Medicine, Zagazig University | ||
| Abstract | ||
| Background: Nonalcoholic fatty liver disease (NAFLD) is a chronic liver disease which includes simple steatosis and nonalcoholic steatohepatitis (NASH). The current study aimed to develop a non-invasive tool to predict NASH in patients with NAFLD. Patients and Methods: A cross-sectional study was carried on (80) patients presenting to the Hepatology /Internal Medicine Outpatient Clinic, Zagazig University Hospitals suffering from dyspeptic symptoms, fatigue and unexplained elevation of aminotransferases from July 2019 to January 2020. All patients were subjected to liver function tests, lipid profile, fasting blood sugar, serological markers, abdominal ultra-sonographic examination and Fibroscan evaluation. The new model score included the following clinical and laboratory parameters [body mass index (BMI), US of liver, Liver stiffness, low-density lipoproteins (LDL), high-density lipoprotein (HDL), triglyceride (TG), Alanine transferase (ALT), Aspartame transaminase (AST), AST/ALT ratio, Platelet, mean platelet volume (MPV), Ferritin and Fasting Blood Glucose] Results: current results showed a sensitivity of the new score in the detection of NASH (97.9%) versus 91.7% and 89.6% for NAFLD score and BARD score respectively, but GULAB score was associated with a 100% sensitivity, at a cutoff level of 1.5. The area under the curve for the new score was is 0.789 versus 0.921, 0.925, and 0.996 for NAFLD, BARD, and GULAB scores respectively. Conclusion: The new model score considered simple, non-invasive and low-cost tool and can be used as a good negative test to exclude NASH in the screening of high risk patients and markedly reduce the need for liver biopsies in NAFLD patients. | ||
| Keywords | ||
| Nonalcoholic steatohepatitis; Steatosis; Fibrosis | ||
|
Statistics Article View: 291 PDF Download: 343 |
||
